Publisher： Elsevier
Founded in： 1978
Total resources： 7
E-ISSN： 1878-1217
ISSN： 1359-6349
Subject： R73 Oncology
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
EJC Supplements
Menu
Delivering optimal adjuvant chemotherapy in primary breast cancer: the role of rHuG-CSF
By Paridaens R., Lyman G.H., Leonard R., Crawford J., Bosly A., Constenla M., Jackisch C., Pettengell R., Szucs T., on behalf of the Impact of Neutropenia in Chemotherapy European Study Group in (2003)
EJC Supplements , Vol. 1, Iss. 9, 2003-11 , pp.
Access to resources
Recommend
Gefitinib ('Iressa', ZD1839): the patients' experience
EJC Supplements , Vol. 1, Iss. 8, 2003-10 , pp.Novel approaches in oncology at AstraZeneca
By Wheeler C., Stephens T., Byth K., Green T., Wedge S., Blakey D., Hughes A. in (2003)
EJC Supplements , Vol. 1, Iss. 8, 2003-10 , pp.Targeting the epidermal growth factor receptor: prognostic and clinical implications
EJC Supplements , Vol. 1, Iss. 8, 2003-10 , pp.The use of taxanes in early breast cancer
EJC Supplements , Vol. 1, Iss. 7, 2003-10 , pp.Clinical benefit in NSCLC: the evidence for gefitinib ('Iressa', ZD1839)
EJC Supplements , Vol. 1, Iss. 8, 2003-10 , pp.Symptoms and quality of life: important patient outcomes?
EJC Supplements , Vol. 1, Iss. 8, 2003-10 , pp.
Previous
Next